DYNO FRONTIERS PROGRAM

Demonstrating the power of innovative genetic payloads

We're partnering with innovative teams at the frontiers of modern medicine to demonstrate the transformative therapeutic potential of breakthrough genetic payloads delivered in vivo by high-performance AAV capsid technology.

Announcing the Dyno Frontiers Program

Today, we're excited to announce the Dyno Frontiers Program, an initiative designed to demonstrate the transformative therapeutic potential of innovative genetic payloads. Through this program Dyno will provide select gene therapy developers with leading-edge AAV capsid delivery technology and advise on NHP study plans to support the demonstration of payload effectiveness for a variety of emerging genetic medicine modalities.

As genetic technologies advance and diversify, gene developers increasingly need high-performance delivery vectors to realize the therapeutic potential of their innovative payload strategies. Many gene therapy developers lack access to the most advanced AAV delivery technology, and even when developers can evaluate new capsids, a lack of standardized methods for quantifying capsid performance can create uncertainty about whether a novel payload strategy will be effective with subsequent generations of capsids. Additionally, emerging payload strategies sometimes require distinct evaluation methods and data-types which generic capsid evaluation metrics don't address–a challenge which requires additional developer resources and time to overcome. Dyno aims to eliminate these barriers, enabling gene therapy developers and their investors to more easily gain the highest levels of confidence in the therapeutic potential of innovative payload strategies. Pairing innovative genetic payloads with high-performance capsid technology and sensitive quantification methods will best showcase the truly transformative potential of these emerging therapeutic modalities.

With the Frontiers Program, Dyno will partner with innovative gene therapy developers who are ready to initiate NHP studies demonstrating payload effectiveness for eye, muscle, or CNS indications, providing access to Dyno’s gene delivery vectors and advisory support from Dyno’s research teams.

Program participants will collaborate with Dyno scientists to:

Leverage Dyno’s AAV capsid technology and demonstrate the in vivo effectiveness of innovative clinic-ready genetic payloads

Program participants will receive access to Dyno’s capsid technology and receive tailored guidance on the design of NHP studies and tips for successful vector manufacturing. By leveraging leading-edge capsids optimized to their target delivery profiles, developers will be able to produce high-quality data with which to demonstrate the therapeutic potential of their clinic-ready genetic payloads.

Enable payload-specific quantification of capsid performance and extrapolation of capsid performance to novel payload strategies

All gene therapies require efficient delivery of genetic payloads to target cells and organs, but a lack of standardization in how capsid performance is measured across studies can often make it challenging for gene therapy developers to infer whether a new capsid will be suitable for delivering a novel therapeutic payload.

Dyno would like to be able to provide every gene therapy developer with the essential information they need to determine whether a given capsid would be sufficient for their therapeutic strategy, no matter whether it employs DNA or RNA editing, novel promoters, dual AAV systems, secreted proteins, etc.

To best enable accurate prediction of payload performance with emerging capsids, Dyno’s team will work with each program participant towards achieving high accuracy quantification of delivery and payload efficacy in vivo. The Dyno Frontiers Program will initially focus on evaluation frameworks for eye, muscle, and CNS–the organs with the highest unmet patient need for gene therapy. Dyno will use this information to help existing program participants to know what to expect from future generations of Dyno’s capsid products, and to help potential partners predict the expected performance of Dyno capsids for novel payload approaches. In this way program participants, Dyno and the broader gene therapy community will gain immediate and long-term benefits.

If you are a scientific team interested in participating in the Dyno Frontiers Program, we encourage you to fill out the form below. We look forward to hearing from you.

Contact us

Interested? Let’s get in touch.

Thank you for your submission to the Dyno Frontiers Program! You can expect to hear back from us about next steps soon.

Oops! Something went wrong while submitting the form.

Important Information